As of July, 18 Swedish Orphan Biovitrum AB (publ) Analysts See $0.21 EPS

June 27, 2018 - By Ashley Bratcher

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Corporate Logo

Earnings report for Swedish Orphan Biovitrum AB (OTCMKTS:publ) is expected on July, 18., as reported by Faxor. If SWTUY’s EPS is $0.21 the profit will be $57.46M for 25.65 P/E. -12.50 % negative EPS growth is what Wall Street’s predicts after $0.24 reported EPS previous quarter. publ is touching $21.55 during the last trading session, after decreased 2.36%.Swedish Orphan Biovitrum AB is after having 0.00% since June 27, 2017. publ has 965 volume or 315.95% up from normal. publ underperformed by 12.57% the S&P 500.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally.The company has $5.90 billion market cap. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.The P/E ratio is 35.5. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.